Q321 results were a letdown compared to the previous quarter as COVID-19 continues to burst HA players’ bubble but hopes for a return to normal prevail.
Spring 2021 brought on much relief to the US Joint Fluid Replacement market and the summer looked promising for a return to normal business conditions. However, as more cases of COVID-19 Delta variant were reported, especially in key hyaluronic acid (HA) states, like Texas and Florida, companies were left as though their bubble got burst. Some players expressed concerns that volumes could be depressed for Q421 since it does not seem to be picking up as fast as they projected. But, for Q321 and for the most part, the majority of HA market players did report positive revenue increases in the third quarter.
Among the many topics covered in detail in our comprehensive Q321 US Joint Fluid Replacement Market Recap* are:
- Complete Q321 US Joint Fluid Market Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- All Competitor Company Financials and Market Shares
- Notable Q321 Developments
Overall, aggregate revenue growth for Q321 was positive vs Q320, mainly due to COVID-19 recovery. According to SmartTRAK Financial Dashboard, the US Joint Fluid Replacement Market was also up ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK has recently expanded it's coverage to include five new modules. Click to see details of all the exciting new additions to the SmartTRAK platform in 2021.
